Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Senate Budget Draft Would Be Less Generous To US FDA Than House For FY2023

Aug 07 2022

• By Derrick Gingery

comparing coins — • Source: Shutterstock

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

Related Content

House ALS Bill Would Require US FDA ‘Action Plan’ – But Not Conditional Approval

Nov 16 2021

US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews

Oct 29 2018

Here We Go Again: US FDA Weighing Accelerated Approval For Biogen’s ALS Drug Tofersen

Jul 27 2022

ALS Drugs: Second US FDA Meeting On AMX0035 Gives Amylyx A Chance To Capitalize On Recent Events

Jul 29 2022

US FDA User Fees: Lay-Off Notices Planned For Early September If Congress Doesn’t Pass Bill

Jul 28 2022

Aduhelm, One Year Later: US FDA’s Credibility, Accelerated Approval Pathway Feel The Bite From Alzheimer’s Drug Approval

Jun 06 2022

Rare Disease Challenges At US FDA: CDER Director Says More Staff, Not Reorganization, Will Fix Issues

Apr 06 2022

Related Companies

Biogen, Inc.

Amylyx Pharmaceuticals, Inc.

Additional Topics

United States Legislation Regulation Rare Diseases FDA User Fees Neurology BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window